Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | LMNA | P02545 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.46 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | WDR5 | P61964 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18186426 | 1.00 | ALDH1A1 (0.60) | ALDH1A1LMNAMAPTRECQLGPR119 | |
| SCHEMBL16824986 | 0.90 | ALDH1A1 (0.58) | ALDH1A1LMNAMAPTRECQLGPR119 | |
| SCHEMBL18186308 | 0.90 | ALDH1A1 (0.58) | ALDH1A1LMNAMAPTRECQLGPR119 | |
| SCHEMBL28094571 | 0.89 | ALDH1A1 (0.46) | ALDH1A1LMNAMAPTRECQLHTT | |
| SCHEMBL28094569 | 0.89 | ALDH1A1 (0.46) | ALDH1A1LMNAMAPTRECQLHTT | |
| SCHEMBL18186263 | 0.87 | ALDH1A1 (0.45) | ALDH1A1LMNAMAPTRECQLMEN1 | |
| SCHEMBL16824867 | 0.87 | ALDH1A1 (0.45) | ALDH1A1LMNAMAPTRECQLMEN1 | |
| SCHEMBL13419658 | 0.86 | MAPT (0.76) | ALDH1A1LMNAMAPTRECQLGPR119 | |
| SCHEMBL18186321 | 0.86 | MAPT (0.76) | ALDH1A1LMNAMAPTRECQLGPR119 | |
| SCHEMBL25405640 | 0.85 | ALDH1A1 (0.61) | ALDH1A1LMNAMAPTRECQLGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850247-B2 | Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors | ALMAC HOUSE (GB) | 2017-12-26 | — | — | US | disclosed |
| EP-3083625-B1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LTD (GB) | 2017-11-01 | — | — | EP | disclosed |
| US-20160318936-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| EP-3083625-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | Almac Discovery Limited (GB) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015092431-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318936-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | WEE1, WEE2, NME1 | ALDH1A1 1940/4885LMNA 3631/4885MAPT 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.